

Development of a Therapeutic Antibody Targeting TCTP for Refractory Colorectal Cancer

NEX-I


 NEX-I
 NEXT-GENERATION
 IMMUNOTHERAPEUTICS

ONCOLOGY	Preclinical
Product Type	Antibody
Indication	MSS CRC
Target	TCTP (Translationally Controlled Tumor Protein)
MoA(Mechanism of Action)	TME Modulator ; Restore anti-tumor activity and immune function by neutralizing TCTP
Competitiveness	<ul style="list-style-type: none"> ✓ Novel target: Inhibition of ICI refractory factor, TCTP ✓ Exclusivity: Recovery of ICI response and immune function ✓ Efficacy: Single and synergistic effects in combination with concurrent ICI ✓ Safety: Low toxicity and favorable safety profile
Development Stage	Preclinical
Route of Administration	Intravenous

Any unauthorized distribution or reproduction of this material is strictly prohibited.